Simtuzumab

Recent research identifies LOXL2 as a primary driver of fibrosis in LMNA-mutated dilated cardiomyopathy. The study demonstrates that Simtuzumab, a LOXL2 inhibitor, effectively prevents extracellular matrix remodeling and preserves cardiac function in both human iPSC and murine models.